menu
    • menu
    [{"orgOrder":0,"company":"Oruka Therapeutics","sponsor":"ARCA Biopharma","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"","productType":"Small molecule","year":"2024","type":"Merger","leadProduct":"ORKA-001","moa":"","graph1":"Dermatology","graph2":"IND Enabling","graph3":"Oruka Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"","sponsorNew":"Oruka Therapeutics \/ Oruka Therapeutics","highestDevelopmentStatusID":"5","companyTruncated":"Oruka Therapeutics \/ Oruka Therapeutics"},{"orgOrder":0,"company":"Oruka Therapeutics","sponsor":"Fairmount","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"","productType":"Small molecule","year":"2024","type":"Private Placement","leadProduct":"ORKA-001","moa":"","graph1":"Dermatology","graph2":"IND Enabling","graph3":"Oruka Therapeutics","amount2":0.28000000000000003,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Dermatology","amount2New":0.28000000000000003,"dosageForm":"","sponsorNew":"Oruka Therapeutics \/ Fairmount","highestDevelopmentStatusID":"5","companyTruncated":"Oruka Therapeutics \/ Fairmount"},{"orgOrder":0,"company":"Oruka Therapeutics","sponsor":"Braidwell LP","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"","productType":"Large molecule","year":"2024","type":"Private Placement","leadProduct":"ORKA-001","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Oruka Therapeutics","amount2":0.20000000000000001,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Oruka Therapeutics \/ Braidwell LP","highestDevelopmentStatusID":"14","companyTruncated":"Oruka Therapeutics \/ Braidwell LP"},{"orgOrder":0,"company":"Oruka Therapeutics","sponsor":"ARCA Biopharma","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"","productType":"Large molecule","year":"2024","type":"Merger","leadProduct":"ORKA-001","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Oruka Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Oruka Therapeutics \/ Oruka Therapeutics","highestDevelopmentStatusID":"14","companyTruncated":"Oruka Therapeutics \/ Oruka Therapeutics"}]

    Find Clinical Drug Pipeline Developments & Deals by Oruka Therapeutics

    Menu

    Oruka Therapeutics

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Oruka Therapeutics

                            U.S.A arrow
                            Compamed
                            Not Confirmed

                            Oruka Therapeutics

                            U.S.A arrow
                            Compamed
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ORKA-001

                            Therapeutic Area : Dermatology

                            Study Phase : IND Enabling

                            Sponsor : Braidwell LP

                            Deal Size : $200.0 million

                            Deal Type : Private Placement

                            DEALS_DEV arrow-down

                            Oruka Therapeutics Announces $200 Million Private Placement

                            Details : The net proceeds from the financing will be used to support the clinical development of ORKA-001, currently being evaluated in early-stage clinical trials for the treatment of psoriasis.

                            Brand Name : ORKA-001

                            Molecule Type : Large molecule

                            Upfront Cash : Undisclosed

                            September 12, 2024

                            Lead Product(s) : ORKA-001

                            Therapeutic Area : Dermatology

                            Highest Development Status : IND Enabling

                            Sponsor : Braidwell LP

                            Deal Size : $200.0 million

                            Deal Type : Private Placement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Oruka Therapeutics

                            U.S.A arrow
                            Compamed
                            Not Confirmed

                            Oruka Therapeutics

                            U.S.A arrow
                            Compamed
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ORKA-001

                            Therapeutic Area : Dermatology

                            Study Phase : IND Enabling

                            Recipient : ARCA Biopharma

                            Deal Size : Undisclosed

                            Deal Type : Merger

                            DEALS_DEV arrow-down

                            ARCA Biopharma Completes Merger with Oruka Therapeutics, Implements Stock Split

                            Details : Through the merger, the company will focus on advancing Oruka’s pipeline of potentially best-in-class biologics, including ORKA-001 (an IL-23p19 inhibitor) for the treatment of plaque psoriasis.

                            Brand Name : ORKA-001

                            Molecule Type : Large molecule

                            Upfront Cash : Undisclosed

                            August 29, 2024

                            Lead Product(s) : ORKA-001

                            Therapeutic Area : Dermatology

                            Highest Development Status : IND Enabling

                            Recipient : ARCA Biopharma

                            Deal Size : Undisclosed

                            Deal Type : Merger

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Oruka Therapeutics

                            U.S.A arrow
                            Compamed
                            Not Confirmed

                            Oruka Therapeutics

                            U.S.A arrow
                            Compamed
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ORKA-001

                            Therapeutic Area : Dermatology

                            Study Phase : IND Enabling

                            Recipient : ARCA Biopharma

                            Deal Size : Undisclosed

                            Deal Type : Merger

                            DEALS_DEV arrow-down

                            ARCA biopharma and Oruka Therapeutics Announce Merger Agreement

                            Details : Through the merger, the company will focus on advancing Oruka’s pipeline of potentially best-in-class biologics, including ORKA-001 (an IL-23p19 inhibitor) for the treatment of plaque psoriasis.

                            Brand Name : ORKA-001

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            April 03, 2024

                            Lead Product(s) : ORKA-001

                            Therapeutic Area : Dermatology

                            Highest Development Status : IND Enabling

                            Recipient : ARCA Biopharma

                            Deal Size : Undisclosed

                            Deal Type : Merger

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Oruka Therapeutics

                            U.S.A arrow
                            Compamed
                            Not Confirmed

                            Oruka Therapeutics

                            U.S.A arrow
                            Compamed
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ORKA-001

                            Therapeutic Area : Dermatology

                            Study Phase : IND Enabling

                            Sponsor : Fairmount

                            Deal Size : $275.0 million

                            Deal Type : Private Placement

                            DEALS_DEV arrow-down

                            ARCA biopharma and Oruka Therapeutics Announce Merger Agreement

                            Details : The net proceeds will be used to advance Oruka’s pipeline of potentially best-in-class biologics, including ORKA-001 (an IL-23p19 inhibitor) for the treatment of plaque psoriasis.

                            Brand Name : ORKA-001

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            April 03, 2024

                            Lead Product(s) : ORKA-001

                            Therapeutic Area : Dermatology

                            Highest Development Status : IND Enabling

                            Sponsor : Fairmount

                            Deal Size : $275.0 million

                            Deal Type : Private Placement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth